<DOC>
	<DOCNO>NCT00103090</DOCNO>
	<brief_summary>RATIONALE : Drugs , fenretinide lonafarnib , may stop growth head neck cancer block blood flow tumor . Fenretinide may also help tumor cell become normal cell . Lonafarnib may also stop growth tumor cell block enzymes need cell growth . Giving fenretinide together lonafarnib may kill tumor cell . PURPOSE : This randomized phase I trial study side effect best dose fenretinide lonafarnib treat patient advanced recurrent head neck cancer .</brief_summary>
	<brief_title>Fenretinide Lonafarnib Treating Patients With Advanced Recurrent Head Neck Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine biological activity tolerability fenretinide lonafarnib patient advance recurrent squamous cell carcinoma head neck . - Determine toxicity profile regimen patient . - Determine maximum tolerate dose regimen patient . Secondary - Determine dose-limiting toxicity regimen patient . - Determine recommend phase II dose regimen patient . OUTLINE : This dose-escalation study follow randomize study . - Dose-escalation portion : Patients receive oral fenretinide twice daily day 1-7 oral lonafarnib twice daily day 1*-21 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos fenretinide lonafarnib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . - Randomized portion : After dose-escalation portion study complete , additional patient ( include patient participate dose-escalation portion study ) accrue randomized 1 4 dose level . All patient receive fenretinide lonafarnib dose-escalation portion study . NOTE : *Lonafarnib administer day 1 course 1 . After completion study treatment , patient follow every 3 month 2 year . PROJECTED ACCRUAL : A total 40 patient accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma head neck Advanced recurrent disease Considered incurable standard measure Tumor tissue accessible biopsy PATIENT CHARACTERISTICS : Age Any age Performance status stern Cooperative Oncology Group ( ECOG ) 01 Life expectancy Not specify Hematopoietic White Blood Count ( WBC ) ≥ 3,000/mm^3 Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL Hepatic Bilirubin ≤ 2.0 mg/dL Albumin ≥ 2.5 g/dL Aspartate aminotransferase ( AST SGOT ) and/or alanine aminotransferase ( ALT SGPT ) ≤ 2.5 time upper limit normal ( ULN ) AND alkaline phosphatase normal OR Alkaline phosphatase ≤ 4 time Upper Limit Normal ( ULN ) AND Aspartate aminotransferase ( AST SGOT ) and/or alanine aminotransferase ( ALT SGPT ) normal Renal Creatinine &lt; 2 mg/dL Cardiovascular No history uncontrolled heart disease No arrhythmia No angina No congestive heart failure No heart condition control regular ongoing medication Gastrointestinal Able swallow oral medication No requirement total parenteral nutrition lipid Neurological No significant neuropathy No neurotoxicity ≥ grade 3 prior anticancer treatment Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective doublemethod contraception least 1 month study participation No sign symptom acute infection require systemic therapy No confusion , disorientation , major psychiatric illness would preclude give informed consent No serious infection require immediate therapy No illness require immediate therapy No preexisting retinopathy No medical social factor would preclude study compliance PRIOR CONCURRENT THERAPY : Biologic therapy See Chemotherapy Chemotherapy No 2 prior chemotherapeutic regimen recurrent metastatic disease Prior biologic therapy consider chemotherapeutic regimen Endocrine therapy More 2 day since prior concurrent highdose chronic steroid More 2 day since prior concurrent ethinylestradiol No concurrent anticancer hormonal therapy Radiotherapy More 6 month since prior radiotherapy No concurrent radiotherapy Surgery No prior surgery may affect ability swallow study drug Other More 2 day since prior concurrent cytochrome P450 3A4 ( CYP3A4 ) inducer inhibitor , include follow : Gestodene Itraconazole Ketoconazole Cimetidine Erythromycin Carbamazepine Phenobarbital Phenytoin Rifampin Sulfinpyrazone Grapefruit juice More 30 day since prior highdose vitamin A No concurrent highdose synthetic natural vitamin A derivative ( &gt; 10,000 IU/day ) No concurrent antioxidant ( e.g. , vitamin E vitamin C ) No concurrent investigational agent No concurrent antineoplastic agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage III squamous cell carcinoma lip oral cavity</keyword>
	<keyword>stage IV squamous cell carcinoma lip oral cavity</keyword>
	<keyword>recurrent squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage III squamous cell carcinoma nasopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma nasopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage III squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>stage IV squamous cell carcinoma paranasal sinus nasal cavity</keyword>
	<keyword>recurrent salivary gland cancer</keyword>
	<keyword>salivary gland squamous cell carcinoma</keyword>
	<keyword>stage III salivary gland cancer</keyword>
	<keyword>stage IV salivary gland cancer</keyword>
	<keyword>recurrent metastatic squamous neck cancer occult primary</keyword>
	<keyword>metastatic squamous neck cancer occult primary squamous cell carcinoma</keyword>
</DOC>